





Patient's Identification Code:	
<u>Introduction</u>	

This standardized Case Report Form (CRF) is the result of an ongoing effort between the World Health Organization (WHO), The Pan-American Health Organization (PAHO), Institute Pasteur (IP), and the networks of ISARIC, CONSISE PREPARE and REACTing to generate standardized clinical and epidemiological research tools.

DESIGN OF THIS CASE REPORT FORM (CRF)

There are sets of Case Report Forms (CRFs) to be used in combination for prospective cohort studies or case control studies. These sets of CRFs are to be used at admission and at discharge/going home. For any patients admitted for more than 24 hours, the Baseline and Outcome CRF and the Laboratory Results CRF can be copied and used for daily data recording.

For all studies, we recommend completing a minimum of the Child Baseline and Outcome (CBO) CRF, follow by Child Acute Symptoms (CAS). If the patient is admitted to a hospital or has further investigations, complete Child Hospital Stay (CHS) and Child Laboratory Results (CLR) CRFs. We recommend completing the Neonatal CRF and the Maternal Baseline and Outcome CRF to capture maternal and/or neonatal risk factors. If the patient is admitted to an Intensive Care Unit or Pediatric Intensive Care Unit, complete Child Intensive Care (CIC) as well. For follow up visit(s) complete Child follow up visit(s) (CFU).

Complete the outcomes sections in the CBO CRF once all diagnostics laboratory results and final diagnosis are available.

HOW TO USE THIS CRF

When completing the CRF modules, please make sure that:

- The patient or consultee/guardian/representative has been given information about the study and the informed consent form has been completed and signed.
- The study ID codes have been assigned for the patient as per hospital protocol and guidelines.
- The study ID codes should be filled in on all pages of paper CRF forms, all information should be kept confidential at all times, and no identifiable information is recorded on the CRFs.
- Patient's hospital ID and contact details are recorded on a separate contact list to allow later follow up. The contact forms must be kept separate from the CRFs at all times and kept in a secure location.

Each site may choose which data to collect based on available resources and the number of patients enrolled to date. Ideally, data on patients will be collected using all CRF modules as appropriate.

Sites with very low resources or very high patient numbers may select **Child Baseline and Outcome (CBO)** CRF module only. The decision is up to the site Investigators and may be changed throughout the data collection period. All high quality data are valuable for analysis.

GENERAL GUIDANCE

- The CRFs are designed to collect data obtained through patient examination, for patient or parent/guardian/representative interview and review of hospital notes.
- Patient ID codes should be filled in on all pages of paper CRF forms.
- Complete every line of every section, except for where the instructions say to skip a section based on certain responses.
- Selections with square boxes (\square) are single selection answers (choose one answer only). Selections with circles (o) are multiple selection answers (choose as many answers as are applicable).
- It is important to indicate when the answer to a particular question is not known. Please mark the 'Unknown' box if this is the case.
- Some sections have open areas where you can write additional information. To permit standardized data entry, please avoid writing additional information outside of these areas.
- We recommend writing clearly in black or blue ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please contact us, if we can help with any CRF completion questions, if you have comments and to let us know that you are using the forms. Please contact Dr Gail Carson by email: gail.carson@ndm.ox.ac.uk







Dationt's	Identification	Code .	
raueni s	identification	code:	

Disclaimer: These CRFs are intended for use as a standardized document for the collection of clinical data in studies investigating the Zika virus. Responsibility for use of these CRFs rests with the study investigators. ISARIC and the authors of the CRF accept no responsibility for the use of the CRF in an amended format nor for the use of the standardized CRF outside its intended purpose. Formatting issues are in the process of being resolved. Word documents are available in order to adapt and translate the CRFs, however, there may be issues between Macs and PCs. The PDF format is also available, which should be well formatted on both systems.

1. Geoposition	Latitude:	Lon	gitude:
2. Name of site/clinic/hospital		·	
If geoposition not available			
3. City/town/village:			
4. Country:			
5. Admitted to hospital	☐ Yes ☐ No ☐ Ui	nknown	
If yes: (also complete form CHS)			
6. If yes, date of admission (dd/mm/yyyy)	_/_/20	7. Date of discharge	// 20
8. Name of hospital admitted to and			
town/city:			
9. Date of onset of first symptoms (dd/mm/yyyy)	_/_/20		

1) INITIAL EXAMINATION

BASELINE OBSERVATIONS AND SIGNS AT PRESE	NTATION (≤24 ho	urs of presentation)
10. Date (dd/mm/yyyy)	//20	_	
11. Maximum Temperature	°C □	°F □	□ Unknown
	□Oral □Tympa	anic □Axillary □A	nal □Skin
12. Respiratory Rate		breaths/minute	□ Unknown
13. Heart Rate		beats/minute	☐ Unknown
14. Systolic Blood Pressure		mmHg	☐ Unknown
15. Diastolic Blood Pressure		mmHg	☐ Unknown
16. Peripheral O ₂ Saturation (SpO ₂)		% Not record	ded 🗌 Unknown
17. Glasgow Coma Score (out of 15) or	/ 15	☐ Unknowr	1
18. AVPU (tick state of consciousness)	□Alert □Respo	onds to verbal stimu	li
	☐ Responds to p	oain stimuli 🔲 Uni	responsive
19. Weight *		□grams □poun	ds/ounces
20. Height *		□cm □feet/I	nches
21. Head circumference *		_ cm	
*Plot metrics in growth curve as per your	22. Current	23. Current length	24. Current head
national guidelines and record the standard	weight	23. Current length	circumference
deviations above (indicated with "+") or below			
(indicated with "-") the mean for age and sex		SD	
	SD		SD
25. Weight loss	□Yes □No □	Unknown	
If yes, specify lost during this current		□ka □nounds/e	ounces
episode of illness		_ □kg □pounds/o	Julices
26. Lymphadenopathy	☐Cervical only	□General □No	□Unknown







Dationt's	Identification	Code .
Patient S	identification	code:

· accent o racinamication o			
27. Enlarged liver	□Yes □No □Unknown	28. Enlarged spleen	□Yes □No □Unknown

Note: If further demographic or epidemiology information is required please use the complementary ZIKV CRF Epidemiology and Demographics

2) SYMPTOMS (since first day of onset of this illness	ss episode)	
29. Amnesia	□Yes □No □U	Inknown
30. Confusion/disorientation	□Yes □No □U	Inknown
31. Altered behavior or personality	□Yes □No □U	Inknown
32. Headache	□Mild □Modera	te □Severe □No □Unknown
33. Photophobia	□Yes □No □L	Inknown
34. Neck stiffness	□Yes □No □L	Inknown
35. Seizures	□General □Foca	I □No □Unknown
36. Paralysis	☐General ☐Asce	nding □No □Unknown
If yes, please describe affected body parts and if prog		
37. Weakness	☐General ☐Foca	
	o Power test o Pa	·
If focal, please describe affected body parts and		
38. Oromotor dysfunction		nknown
39. Movement disorder	☐Yes ☐No ☐Ur	
40. Shortness of breath	☐Yes ☐No ☐Ur	
41. Sore throat	☐Yes ☐No ☐Ur	
42. Cough	☐Yes ☐No ☐Ur	
43. Rhinitis	☐Yes ☐No ☐Ur	
44. Chest pain	☐Yes ☐No ☐Ur	
45. Back pain	□Yes □No □Ur	
46. Myalgia	☐Yes ☐No ☐Ur	
47. Arthralgia	□Yes □No □Ur	
48. Joint swelling	☐Yes ☐No ☐Ur	
If yes, specify all affected joints:	o Fingers o Toes	
49. Conjunctivitis	☐Yes ☐No ☐Ur	no if yes specify:
If yes, specify if:		
50. Retro-orbital pain		n-purulent nknown
51. Periorbital pain		nknown
52. Rash		nknown
If yes, please check box for type of rash and specify lo		Spread of the rash:
53. Maculopapular rash	□Yes □No	☐ Centrifugal ☐ Centripetal
Too made paper in the second		Location:
54. Erythematous rash	□Yes □No	☐Centrifugal ☐Centripetal Location:
		Location.







Patient's Identification Co	de :			-	
55. Non blanching rash		□Y	es 🗆 No	□Centrifuga	I □Centripetal
				Location:	·
56. Vesicular rash		□Y	es 🗆 No	☐Centrifuga	I □Centripetal
				Location:	
57. Erythema migrans		□Y	es 🗆 No	☐Centrifuga	I □Centripetal
				Location:	
58. Pruritic rash		□Y	es 🗆 No	□Centrifuga	I □Centripetal
				Location:	
59. Petechial or purpuric	rash	□Y	es 🗆 No	□Centrifuga	I □Centripetal
				Location:	
60. Bruising/ ecchymosis		□Y	es 🗆 No	□Centrifuga	I □Centripetal
				_	
61. If other type of rash,	please specify type and	Тур	e:		
spread:		O F	ace O Torso C	O Upper limbs	O Lower limbs
		O P	alms O Other:		
62. Pruritus		□Y	es 🗆 No 🗆 Ui	nknown	
If yes, specify:			Seneralized 🛘	Localized	
63. Jaundice		□Y	es 🗆 No 🗀 Ui	nknown	
64. Sign of insect bites		□Y	es 🗆 No 🗀 Ui	nknown	
65. Bleeding		□Ye	es 🗆 No 🗆 Ui	nknown	
If yes, please state s	ource:		ruising O Gum		Hematemesis
, 50, p. 6400 64400 6	- a c.		Telena or fresh		
			ematuria O Va	•	r. specify:
				Ü	, , ,
66. Mouth ulcers		□Y	es 🗆 No 🗆 Ui	nknown	
67. Diarrhea		□Y	es 🗆 No 🗀 Ui	nknown	
68. Vomiting/nausea		□Y	es 🗆 No 🔲 Ui	nknown	
69. Stomach pain		□Y	es 🗆 No 🗀 Ui	nknown	
70. Other (specify):					
(1 //					
3) Treatment					
•					
	(from onset of symptoms)				
	nistered for acute symptoms	. Use	generic names	and list all tre	atment given to the
patient for this illness epis	1				
Type of medication	Name of medication and do	ose	Start date	Number	Route of
	(generic name)		(dd/mm/yyyy)	of days	administration
71. Antibiotics					□IV □Oral
□Yes □No					□™
72. Antivirals					□IV □Oral
□Yes □No					
72 Auti inflammatan /					
73. Anti-inflammatory/					□IV □Oral
Antipyretics					
□Yes □No					







74. Corticosteroids Yes No 75. Anticonvulsants Yes No 76. Immunoglobulins Yes No 77. Other (specify):	
75. Anticonvulsants Yes No 76. Immunoglobulins Yes No 77. Other (specify): Other (specify):	□IV □Oral □IV □Oral □Subcut □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □IV □Oral
☐Yes ☐No 76. Immunoglobulins ☐Yes ☐No 77. Other (specify): Other (specify):	□IV □Oral □Subcut □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □IV □Oral □IV □Oral □IV □Oral □IV □Oral
76. Immunoglobulins Yes No 77. Other (specify): Other (specify):	□Subcut □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □IV □Oral □IV □Oral □IV □Oral □IV □Oral
☐Yes ☐No 77. Other (specify): Other (specify):	□Subcut □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □IV □Oral □IV □Oral □IV □Oral □IV □Oral
77. Other (specify): Other (specify):	□IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □IV □Oral □Topical □Inhaled
Other (specify):	□Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled
	□Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled □Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled
	☐IM ☐Sublingual ☐IV ☐Oral ☐Topical ☐Inhaled ☐Subcut ☐PR ☐IM ☐Sublingual ☐IV ☐Oral ☐IV ☐Oral ☐Topical ☐Inhaled
	☐IV ☐Oral ☐Topical ☐Inhaled ☐Subcut ☐PR ☐IM ☐Sublingual ☐IV ☐Oral ☐Topical ☐Inhaled
	☐IV ☐Oral ☐Topical ☐Inhaled ☐Subcut ☐PR ☐IM ☐Sublingual ☐IV ☐Oral ☐Topical ☐Inhaled
	□Subcut □PR □IM □Sublingual □IV □Oral □Topical □Inhaled
	□IM □Sublingual □IV □Oral □Topical □Inhaled
	□IV □Oral □Topical □Inhaled
•	☐Topical ☐Inhaled
Other (specify):	· · · · · · · · · · · · · · · · · · ·
	□Subcut □PR
	☐IM ☐Sublingual
Other (specify):	□IV □Oral
	☐Topical ☐Inhaled
	□Subcut □PR
	☐IM ☐Sublingual
4) TRANSFER TO OTHER HOSPITAL	
78. Was the patient transferred to	
another hospital?	Yes □No □Unknown
79. If yes, please state name of the	spital name:
hospital and city (address if possible): Cit	y/Town/Village:
80. Please state reason for transfer:	
If admitted to intensive care unit, please also	complete form CIC
,, <u></u>	
5) CASE REPORT FORM COMPLETE	D BY
Name and role	
Signature	Date (dd/mm/yyyy)